Severe persistent asthma represents the most clinically challenging, therapeutically demanding, and prognostically serious end of the asthma severity spectrum, affecting approximately five to ten percent of the asthma population but accounting for more than fifty percent of asthma-related healthcare costs, hospitalizations, and mortality. Despite these disproportionate clinical and economic impacts, severe asthma remains one of the most heterogeneous and incompletely understood conditions in respiratory medicine, encompassing multiple distinct disease subtypes with different underlying mechanisms, different biological profiles, different responses to available treatments, and therefore requiring fundamentally different management approaches. The characterization of severe asthma as a single disease entity has increasingly given way to a precision medicine framework that recognizes distinct severe asthma phenotypes and endotypes, stratifies patients by their predominant immunological mechanisms, and targets treatment accordingly with the growing portfolio of biological therapies that have transformed severe asthma management over the past two decades.
The diagnostic category of severe asthma, as defined by the European Respiratory Society and American Thoracic Society joint task force guidelines, requires the demonstration that asthma remains uncontrolled despite adherence to maximal optimized treatment with high-dose inhaled corticosteroids combined with a second controller medication such as a long-acting beta-2 agonist, leukotriene receptor antagonist, or theophylline, or that a reduction in the high-dose treatment produces loss of asthma control. This definition is critically important because it requires the exclusion of poor inhaler technique, suboptimal adherence, inadequately treated comorbidities, and misdiagnosis of alternative conditions mimicking asthma before accepting that a patient’s disease is genuinely treatment-refractory rather than simply undertreated.
Phenotyping and Endotyping Severe Asthma
The clinical phenotyping of severe asthma, which groups patients by observable clinical characteristics without necessarily specifying the underlying molecular mechanisms, and biological endotyping, which characterizes the specific immunological and molecular pathways driving the disease, together provide the framework for precision medicine approaches to severe asthma management. The most clinically important phenotypic distinction is between type 2 high severe asthma, in which the disease is driven by the Th2 immunological pathway and characterized by elevated blood and sputum eosinophil counts, elevated fractional exhaled nitric oxide, elevated total and allergen-specific immunoglobulin E, and allergic sensitization, and type 2 low severe asthma, in which eosinophilia and markers of Th2 inflammation are absent and the disease is driven by non-Th2 mechanisms that are less well characterized and for which fewer specifically targeted biological treatments are currently available.
Type 2 high severe asthma itself encompasses several distinct sub-phenotypes that differ in their specific biological features and therefore in their optimal treatment targets. Allergic severe asthma, characterized by sensitization to perennial indoor allergens and elevated total and allergen-specific serum immunoglobulin E, is the predominant phenotype in younger severe asthma patients and responds specifically to anti-immunoglobulin E treatment with omalizumab. Late-onset eosinophilic asthma, which develops in adulthood without clear allergic sensitization and is driven by eosinophilic airway inflammation without immunoglobulin E elevation, responds optimally to anti-interleukin-5 pathway treatments targeting eosinophil survival and recruitment. Aspirin-exacerbated respiratory disease, a syndrome of severe asthma combined with chronic rhinosinusitis with nasal polyps and sensitivity to aspirin and NSAIDs, is driven by arachidonic acid metabolism dysregulation producing excessive cysteinyl leukotriene production and responds specifically to leukotriene modifying therapies and aspirin desensitization protocols.
Type 2 low severe asthma, which affects approximately thirty to forty percent of severe asthma patients, presents the greatest unmet therapeutic need in the field. These patients lack the eosinophilic inflammation that is the primary target of the most effective current biological therapies, have often already failed multiple biological treatment trials, and continue to experience frequent exacerbations and chronic symptom burden on maximally tolerated inhaled therapy. The biological mechanisms driving type 2 low severe asthma are heterogeneous and include neutrophilic airway inflammation, paucigranulocytic inflammation, airway smooth muscle hyperreactivity, and obesity-related mechanisms, reflecting a group of mechanistically distinct conditions that share the common feature of poor responsiveness to standard anti-inflammatory treatments.
Systemic Corticosteroid Dependence and Complications
A critical clinical challenge in severe persistent asthma is the dependence on oral corticosteroids that develops in a substantial proportion of patients whose disease cannot be adequately controlled by inhaled therapy alone. Oral corticosteroids provide powerful suppression of airway inflammation and are effective for controlling severe asthma symptoms and preventing life-threatening exacerbations, but their chronic use produces a devastating array of systemic adverse effects that themselves generate significant morbidity and mortality independent of the asthma they are treating. Adrenal suppression, osteoporosis with vertebral and long bone fractures, hyperglycemia and new-onset diabetes, hypertension, cataracts, glaucoma, weight gain and metabolic syndrome, psychiatric effects including mood disturbance and psychosis, and the characteristic cushingoid features of redistribution of body fat and skin fragility are the principal complications of chronic oral corticosteroid use that impose enormous additional burden on severe asthma patients already living with a severely limiting respiratory disease.
The reduction or elimination of oral corticosteroid dependence is one of the most important therapeutic objectives in severe asthma management, and the capacity of biological therapies to produce oral corticosteroid-sparing effects is a major component of their clinical value alongside their direct effects on asthma control and exacerbation frequency. Clinical trials of mepolizumab and benralizumab in oral corticosteroid-dependent eosinophilic severe asthma have demonstrated median reductions in oral corticosteroid dose of approximately fifty percent compared to placebo, with a substantial proportion of treated patients achieving complete discontinuation of oral corticosteroids while maintaining or improving asthma control. These oral corticosteroid-sparing effects produce meaningful reductions in corticosteroid-related morbidity alongside the direct asthma benefits of biological therapy.
Biological Therapies for Severe Asthma
The biological therapy landscape for severe asthma has expanded dramatically over the past two decades, providing a growing portfolio of highly targeted treatment options for patients with specific immunological phenotypes. Omalizumab, a monoclonal antibody that binds free immunoglobulin E in the circulation and prevents its binding to high-affinity receptors on mast cells and basophils, was the first biological therapy approved for severe asthma and remains an important option for patients with allergic severe asthma characterized by elevated total immunoglobulin E and sensitization to perennial allergens. By depleting free immunoglobulin E, omalizumab reduces mast cell and basophil activation in response to allergen exposure, producing reductions in exacerbation frequency of approximately twenty-five percent compared to placebo in clinical trials of optimized treated patients.
Mepolizumab and reslizumab, monoclonal antibodies targeting interleukin-5, and benralizumab, a monoclonal antibody targeting the interleukin-5 receptor alpha chain, have collectively established anti-interleukin-5 pathway therapy as the most effective pharmacological approach for severe eosinophilic asthma. These agents reduce blood and tissue eosinophil counts through complementary mechanisms, with benralizumab producing the most profound and rapid eosinophil depletion through antibody-dependent cell-mediated cytotoxicity in addition to interleukin-5 receptor blockade. Clinical trial evidence for all three agents demonstrates significant reductions in exacerbation frequency, improvements in lung function, and oral corticosteroid-sparing effects in patients with blood eosinophil counts above threshold levels, with greater benefit consistently observed in patients with higher baseline eosinophilia.
Dupilumab, a monoclonal antibody targeting the shared receptor component of the interleukin-4 and interleukin-13 signaling pathway, provides the broadest biological coverage of type 2 asthma mechanisms among current approved agents, blocking both the B lymphocyte class switching to immunoglobulin E production driven by interleukin-4 and the goblet cell metaplasia, mucus hypersecretion, and airway remodeling driven by interleukin-13 simultaneously. Its efficacy in severe asthma is not restricted to highly eosinophilic phenotypes, extending to patients with moderate eosinophilia and elevated fractional exhaled nitric oxide, and its concurrent approval for atopic dermatitis and chronic rhinosinusitis with nasal polyps makes it particularly suited to patients with severe asthma in the context of multiple type 2 inflammatory comorbidities.
Multidisciplinary Management and Future Perspectives
The optimal management of severe persistent asthma requires a comprehensive multidisciplinary approach that extends well beyond biological therapy selection to address the multiple factors that contribute to disease burden in this complex patient population. Systematic assessment and treatment of comorbid conditions that worsen asthma control or mimic asthma symptoms, including gastroesophageal reflux disease, obstructive sleep apnea, chronic rhinosinusitis, vocal cord dysfunction, anxiety, depression, and obesity, is a prerequisite for accurate assessment of the degree to which symptoms reflect genuine severe asthma rather than comorbid conditions. Respiratory physiotherapy addressing dysfunctional breathing patterns, mucus clearance techniques, and breathing retraining can meaningfully reduce symptom burden in patients whose dysfunctional breathing contributes to their respiratory limitation alongside airway pathology.
The assessment of severe asthma in specialist centers provides the systematic biological phenotyping, comorbidity evaluation, medication optimization, and precision treatment selection that is not achievable in generalist settings, and referral to specialist severe asthma services is recommended for all patients whose asthma remains uncontrolled despite optimized standard treatment. Future directions in severe asthma management include the development of treatments targeting the upstream type 2 alarmin cytokines thymic stromal lymphopoietin, interleukin-25, and interleukin-33, which initiate the Th2 immune cascade and whose blockade may provide even broader anti-inflammatory coverage than current pathway-specific biologicals. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody recently approved for severe asthma, has demonstrated significant exacerbation reductions across all severe asthma phenotypes regardless of baseline eosinophil count or immunoglobulin E level, representing the first biological therapy with demonstrated efficacy across the full severe asthma population including type 2 low phenotypes.